InsiderClue
Stocks · Health care · In Vitro & In Vivo Diagnostic Substances

Intellia Therapeutics, Inc.

NTLA Clue Score53
United States Fiscal year ends December CIK 0001652130 Results filed 5 Nov 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

14
Insider
Date
Role
Action
Shares
Price
Amount
John M Leonard
2 Nov 2026
President and CEO
Sold on a plan
9,000
$11.99
$107.91K
John M Leonard
21 Aug 2026
President and CEO
Sold on a plan
2,785
$13.00
$36.21K
John M Leonard
20 Aug 2026
President and CEO
Sold on a plan
19,890
$12.60
$250.61K
Edward J Dulac III
2 Jul 2026
EVP, Chief Financial Officer
Sold on a plan
4,677
$18.00
$84.19K
Jesse Goodman
1 Jul 2025
Director
Sold on a plan
1,547
$9.23
$14.28K
Jesse Goodman
30 Jun 2025
Director
Sold on a plan
1,547
$9.56
$14.79K
Muna Bhanji
29 Apr 2025
Director
Sold on a plan
265
$8.50
$2.25K
Muna Bhanji
29 Jan 2025
Director
Sold on a plan
265
$9.97
$2.64K
Frank Verwiel
17 Jun 2024
Director
Sold on a plan
1,505
$25.00
$37.63K
Laura Sepp-Lorenzino
8 Jan 2024
EVP, Chief Scientific Officer
Sold on a plan
667
$29.38
$19.60K
Laura Sepp-Lorenzino
8 Jan 2024
EVP, Chief Scientific Officer
Sold on a plan
1,608
$28.66
$46.09K
Muna Bhanji
31 Oct 2023
Director
Sold on a plan
265
$23.90
$6.33K
Muna Bhanji
31 Jul 2023
Director
Sold on a plan
265
$42.33
$11.22K
Muna Bhanji
6 Jul 2023
Director
Sold on a plan
1,867
$39.30
$73.37K
Showing 250 of 298 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 289
Amendments (4/A) skipped 6
Filings about a different issuer 0
Unreadable filings 0
Joint filings 5
Sales on a Rule 10b5-1 plan 14
Sales straight out of an exercise 158
Sales at will 115
Transactions with no price 1
Shares from compensation/vesting 4,470,192
Sales filed before the plan box existed 75
History held since 9 May 2016